Geroprotective effect of thymalin and epithalamin

This 2002 paper in *Advances in Gerontology* (Russian: *Uspekhi Gerontologii*) is the long-duration human geroprotective study from the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology — the dataset most often cited (and most often misrepresented) in the modern Russian-peptide longevity discourse. The researchers followed 266 elderly participants over 6–8 years, comparing those receiving Thymalin (a polypeptide fraction extracted from calf thymus) or Epithalamin (a polypeptide fraction extracted from calf pineal gland) — or both, annually — against age-matched controls. Outcomes were broad: cardiovascular, endocrine, immune, and nervous system parameters; acute respiratory disease incidence; clinical manifestations of ischemic heart disease, hypertension, osteoarthritis, and osteoporosis; and all-cause mortality. The headline numbers reported in the abstract: acute respiratory disease incidence dropped 2.0–2.4-fold in treated groups; mortality dropped 2.0–2.1-fold with Thymalin alone, 1.6–1.8-fold with Epithalamin alone, 2.5-fold with the combination, and 4.1-fold in the subgroup that received the combination annually for the full six-year window — all referenced against age-matched controls. The investigators frame the mechanism as "homeostasis restoration" via peptide-mediated bioregulation across multiple endocrine and immune axes. This is the substrate from which the modern Khavinson-peptide commercial line (and the synthetic peptides Epitalon and Vilon, derived as the active fragments of these extracts) was developed. Two structural caveats matter immediately: the paper studies the natural-extract precursors (Thymalin, Epithalamin), NOT the modern synthetic short peptides — Epitalon (Ala-Glu-Asp-Gly) and synthetic thymic peptides came later and are mechanistically related but not identical. And the methodology is observational with non-randomized cohort assignment, which is the same fundamental concern that limits any long-duration peptide-and-aging dataset. The full text is in Russian; this entry is the editorial summary backed by the published English abstract. The complete translation is in the queue.

The trial is non-randomized, non-blinded, and conducted by the institute that developed and now commercializes the Khavinson peptide line — both meaningful conflicts of interest in long-duration mortality studies where small effects on baseline characteristics can produce large effects on long-term outcomes. The "control" cohort design is described only at abstract-level granularity in the publicly available text; the methodological detail required to evaluate selection bias (matching procedure, refusal rate, attrition handling) is not visible from the abstract alone. The materials studied — Thymalin and Epithalamin — are polypeptide *fractions* from animal-tissue extracts, not the modern synthetic short peptides that the Khavinson group later isolated as the "active fragments" (Vilon = Lys-Glu for thymic activity; Epitalon = Ala-Glu-Asp-Gly for pineal activity). Translating this geroprotective evidence onto the synthetic peptides is a one-step inference that is plausible but not directly demonstrated in the same long-duration human cohort. The paper has not been independently replicated outside the original Russian research group's network. The modern English-language literature on Epitalon and Vilon cites this paper but reports shorter-duration mechanistic studies (telomerase activation, gene expression) rather than independent long-duration mortality replications. The "4.1-fold mortality reduction" headline is the load-bearing claim that has shaped the entire Khavinson-peptide commercial narrative; it has stood unreplicated for over two decades, which is itself information.